Governors Lane LP Purchases 238,800 Shares of Drugs Made In America Acquisition Corp. $DMAA

Governors Lane LP lifted its position in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 2,132.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 250,000 shares of the company’s stock after acquiring an additional 238,800 shares during the quarter. Governors Lane LP’s holdings in Drugs Made In America Acquisition were worth $2,594,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Sandia Investment Management LP bought a new position in shares of Drugs Made In America Acquisition during the 3rd quarter worth $161,000. Quarry LP bought a new stake in Drugs Made In America Acquisition during the third quarter valued at about $161,000. Radcliffe Capital Management L.P. boosted its position in Drugs Made In America Acquisition by 3.5% during the fourth quarter. Radcliffe Capital Management L.P. now owns 546,808 shares of the company’s stock valued at $5,673,000 after purchasing an additional 18,708 shares in the last quarter. Shaolin Capital Management LLC boosted its position in Drugs Made In America Acquisition by 50.0% during the third quarter. Shaolin Capital Management LLC now owns 150,000 shares of the company’s stock valued at $1,540,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Bulldog Investors LLP boosted its position in Drugs Made In America Acquisition by 78.5% during the third quarter. Bulldog Investors LLP now owns 130,264 shares of the company’s stock valued at $1,338,000 after purchasing an additional 57,300 shares in the last quarter.

Drugs Made In America Acquisition Price Performance

Shares of DMAA stock opened at $10.62 on Thursday. Drugs Made In America Acquisition Corp. has a 1-year low of $10.17 and a 1-year high of $10.63. The stock’s 50-day moving average is $10.58 and its 200 day moving average is $10.48.

Drugs Made In America Acquisition (NASDAQ:DMAA) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.06 earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research report on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.